Connor, Clark & Lunn Investment Management »

Karyopharm Therapeutics shares owned by Connor, Clark & Lunn Investment Management

Quarter-by-quarter ownership of Karyopharm Therapeutics (KPTI) shares owned by Connor, Clark & Lunn Investment Management from 13F filings

Historical chart of Connor, Clark & Lunn Investment Management investment in Karyopharm Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Karyopharm Therapeutics held by Connor, Clark & Lunn Investment Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Karyopharm Therapeutics by Connor, Clark & Lunn Investment Management

Quarter filed Position value Share count Share price at filing
2025-12-31 $421k 57k 7.36

More positions owned by Connor, Clark & Lunn Investment Management

Rbc Cad (RY)
Agnico (AEM)
Shopify Cl A Sub Vtg Shs (SHOP)
Toronto Dominion Bk Ont Com New (TD)
Cibc Cad (CM)
NVIDIA Corporation (NVDA)
Bk Nova Cad (BNS)
Apple (AAPL)
Invesco Exch Traded Fd Tr Ii Purbta Msci Us (PBUS)
Microsoft Corporation (MSFT)
Tc Energy Corp (TRP)
Celestica (CLS)
Enbridge (ENB)
Amazon (AMZN)
Barrick Mng Corp Com Shs (B)

View all positions for Connor, Clark & Lunn Investment Management

Top funds holding Karyopharm Therapeutics

T. Rowe Price Investment Management
Opaleye Management
Affinity Asset Advisors
Susquehanna International
Vanguard Group
Ikarian Capital
Soleus Capital Management
Adage Capital Partners GP
Davidson Kempner Capital Management
Braidwell
Exome Asset Management
Ameriprise Financial
Boxer Capital Management
BlackRock
Geode Capital Management

View all funds holding Karyopharm Therapeutics